MCID: HMN021
MIFTS: 38

Human T-Cell Leukemia Virus Type 1

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 19
Human T Lymphotropic Virus Type 1 19
Htlv-1 19

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

GARD: 19 Human T-cell leukemia virus, type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell). Although this virus generally causes no symptoms, some affected people may later develop adult T-cell leukemia (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It may be passed from mother to child during birth or breast-feeding.

MalaCards based summary: Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to adult t-cell leukemia/lymphoma and tropical spastic paraparesis. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are Cellular responses to stimuli and Organelle biogenesis and maintenance. The drugs Pentoxifylline and Mogamulizumab have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone marrow, and related phenotype is Increased hepcidin::fluc mRNA expression.

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the Leukemia, T-Cell, Chronic family:

Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 571)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia/lymphoma 11.7
2 tropical spastic paraparesis 11.7
3 t-cell acute lymphoblastic leukemia 11.6
4 leukemia, t-cell, chronic 11.6
5 infective dermatitis associated with htlv-1 11.6
6 leukemia 11.4
7 spinal cord disease 11.2
8 hereditary spastic paraplegia 11.1
9 spastic paraparesis 11.1
10 pars planitis 11.1
11 intermediate uveitis 11.1
12 t-cell prolymphocytic leukemia 11.1
13 human immunodeficiency virus type 1 10.9
14 human t-cell leukemia virus type 2 10.9
15 t-cell adult acute lymphocytic leukemia 10.9
16 lymphoma 10.7
17 immune deficiency disease 10.6
18 burkitt lymphoma 10.6
19 adult syndrome 10.6
20 uveitis 10.6
21 chronic bilirubin encephalopathy 10.6
22 rheumatoid arthritis 10.6
23 down syndrome 10.6
24 severe combined immunodeficiency 10.6
25 stomatitis 10.6
26 dermatitis 10.5
27 hepatitis c virus 10.5
28 lymphoproliferative syndrome 10.5
29 hepatitis c 10.5
30 viral infectious disease 10.5
31 leukemia, chronic lymphocytic 10.5
32 retinoblastoma 10.5
33 acquired immunodeficiency syndrome 10.5
34 b-cell lymphoma 10.5
35 arthritis 10.5
36 primary agammaglobulinemia 10.5
37 fungal infectious disease 10.4
38 polymyositis 10.4
39 mycosis fungoides 10.4
40 myopathy 10.4
41 adrenocortical carcinoma, hereditary 10.4
42 lymphoma, hodgkin, classic 10.4
43 osteogenic sarcoma 10.4
44 sjogren syndrome 10.4
45 leukemia, acute lymphoblastic 10.4
46 helix syndrome 10.4
47 reading disorder 10.4
48 hematologic cancer 10.4
49 vaccinia 10.4
50 cytokine deficiency 10.4

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased hepcidin::fluc mRNA expression GR00253-A 8.32 CRTC3

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
3 Radiation-Protective Agents Phase 3
4 Phosphodiesterase Inhibitors Phase 3
5 Vasodilator Agents Phase 3
6 Platelet Aggregation Inhibitors Phase 3
7 Antioxidants Phase 3
8 Protective Agents Phase 3
9
Etoposide Approved Phase 2 33419-42-0 36462
10
Lenalidomide Approved Phase 2 191732-72-6 216326
11
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
12
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
13
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
14
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
15
Zidovudine Approved Phase 2 30516-87-1 35370
16
Lenograstim Approved, Investigational Phase 2 135968-09-1
17
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
18
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3
19
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
20
Rituximab Approved Phase 2 174722-31-7
21
Teriflunomide Approved Phase 1, Phase 2 108605-62-5, 163451-81-8 54677977 54684141
22
Nivolumab Approved Phase 2 946414-94-4
23 Anti-Bacterial Agents Phase 2
24 Antineoplastic Agents, Hormonal Phase 2
25 Alkylating Agents Phase 2
26
Etoposide phosphate Phase 2 16760419
27 Antineoplastic Agents, Alkylating Phase 2
28 Hormones Phase 2
29 Antimitotic Agents Phase 2
30 Hormone Antagonists Phase 2
31 Angiogenesis Inhibitors Phase 2
32 Tubulin Modulators Phase 2
33 glucocorticoids Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Liposomal doxorubicin Phase 2
36 Antimetabolites Phase 2
37 Reverse Transcriptase Inhibitors Phase 2
38 Interferon alpha-2 Phase 2
39 Lamivudine, zidovudine drug combination Phase 2
40 interferons Phase 2
41 Interferon-alpha Phase 2
42 Adjuvants, Immunologic Phase 2
43 Interferon-beta Phase 2
44 Antirheumatic Agents Phase 2
45 Anti-Inflammatory Agents Phase 1, Phase 2
46 Immunosuppressive Agents Phase 1, Phase 2
47 Immunologic Factors Phase 2
48 Analgesics Phase 1, Phase 2
49 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
50 Analgesics, Non-Narcotic Phase 1, Phase 2

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
2 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
3 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Terminated NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
4 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
5 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
6 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
7 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
8 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
9 Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy Recruiting NCT04004819 Phase 2 Rituximab
10 Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis Recruiting NCT04799288 Phase 1, Phase 2 Teriflunomide
11 Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) Terminated NCT03075553 Phase 2
12 Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Withdrawn NCT01620736 Phase 2 Raltegravir
13 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
14 Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy Unknown status NCT02961712 Phase 1
15 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
16 A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM) Recruiting NCT05240612 Phase 1
17 A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) Recruiting NCT04301076 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
18 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
19 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
20 Therapeutic Effect of the Pilates Method in People With HAM/TSP: a Randomized Crossover Study Completed NCT04830319
21 Sensorimotor Exercises in Virtual Reality Platform and Balance in Individuals With Human T-lymphotropic Virus Completed NCT02877030
22 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
23 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
24 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
25 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
26 Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) Recruiting NCT00001778
27 Physical Functional Impacts of Rehabilitation in Patients With Human Lymphotropic Virus Type I Recruiting NCT04875403
28 Caractérisation Clinico- Biologique et Survie Des Patients Porteurs d'Une lymphoprolifération HTLV-1 Induite (ou Lymphome/leucémie lié au Virus HTLV-1) et Des Patients infectés Par le Virus HTLV-1 Recruiting NCT05237245
29 Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection Recruiting NCT00001582

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

Organs/tissues related to Human T-Cell Leukemia Virus Type 1:

MalaCards : T Cells, Breast, Bone Marrow, Bone, Spinal Cord, Brain, Monocytes

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 5864)
# Title Authors PMID Year
1
ANK Therapeutic Prospects and Usefulness of PD-L1 and NK Activity as Biomarkers for Predicting Treatment Efficacy Revealed from the Treatment Course of Patients with HTLV-1-Associated Bronchioloalveolar Disease. 62
36282976 2023
2
[Retracted] Effects of nutrients on matrix metalloproteinases in human T‑lymphotropic virus type 1 positive and negative malignant T‑lymphocytes. 62
36367176 2023
3
Increasing horizontal transmission of human T-cell leukemia virus type 1 in adolescents and young adults in Japan. 62
36370501 2022
4
Regulation of human T-cell leukemia virus type 1 antisense promoter by myocyte enhancer factor-2C in the context of adult T-cell leukemia and lymphoma. 62
35615924 2022
5
Molecular insight into the study of adult T-cell leukemia/lymphoma (ATLL): Ten-year studies on HTLV-1 associated diseases in an endemic region. 62
36108787 2022
6
A frequent PLCγ1 mutation in adult T-cell leukemia/lymphoma determines functional properties of the malignant cells. 62
36442790 2022
7
HTLV-1 infection of donor-derived T cells might promote acute graft-versus-host disease following liver transplantation. 62
36450748 2022
8
Development of a Novel HTLV-1 Protease: Human Fcγ1 Recombinant Fusion Molecule in the CHO Eukaryotic Expression System. 62
36399306 2022
9
Establishment of a Cynomolgus Macaque Model of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Direct Inoculation of Adult T-Cell Leukemia Patient-Derived Cell Lines for HTLV-1 Infection. 62
36314828 2022
10
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma. 62
36446869 2022
11
HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. 62
36437745 2022
12
Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein (tTax-tEnv:mFcγ2a) for HTLV-1 vaccine development. 62
36044973 2022
13
Frequency and characteristics of HTLV in migrants: results from the +Redivi collaborative network in Spain. 62
35166822 2022
14
Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4+ T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines. 62
36354340 2022
15
Dynamics and consequences of the HTLV-1 proviral plus-strand burst. 62
36441826 2022
16
HTLV-1 Coinfection among Patients Attending a Large HIV Treatment Centre in Trinidad. 62
36363801 2022
17
Current Interventions to Prevent HTLV-1 Mother-to-Child Transmission and Their Effectiveness: A Systematic Review and Meta-Analysis. 62
36363819 2022
18
Decline in human T-cell lymphotropic virus seroprevalence in blood donors from Minas Gerais, Brazil over a 12-year period (2006-2017). 62
35855523 2022
19
Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA Vectors. 62
36298575 2022
20
Intravenous immunoglobulin infusion contributes to a high incidence of false reactive screen results for human T-lymphotropic virus. 62
35534285 2022
21
Chicken TAX1BP1 suppresses type I interferon production via degrading chicken MAVS and facilitates infectious bursal diseases virus replication. 62
35793720 2022
22
Prevalence and Risk Factors for HTLV-1/2 Infection inRiverside and Rural Populations of the State of Pará. 62
36298817 2022
23
Discordance in the morphologic diagnosis of lymphocytes in HTLV-1-infected individuals. 62
35702819 2022
24
Mannose binding lectin-associated serine protease 2 (MASP2) gene polymorphism and susceptibility to human T-lymphotropic virus type 1 (HTLV-1) infection in blood donors from Mashhad, Iran. 62
35924689 2022
25
Development of a nested real time PCR/high resolution melting assay for human T-cell lymphotropic viruses types 1 and 2 (HTLV-1 and 2) identification. 62
35634751 2022
26
VEGF Polymorphism rs3025039 and Human T-Cell Leukemia Virus 1 (HTLV-1) Infection among Older Japanese Individuals: A Cross-Sectional Study. 62
36290496 2022
27
Comparison of Static Balance Control in Infected Htlv-1 Subjects with Different Tsp/Ham Diagnosis. 62
36366437 2022
28
Postural Adjustments in HTLV-1 Infected Patients during a Self-Initiated Perturbation. 62
36366487 2022
29
Herpes simplex virus type 2 (HSV-2) and its association with HIV, HCV, HBV, HTLV-1&2 and syphilis among men who have sex with men in Burkina Faso. 62
36241531 2022
30
Duodenal obstruction due to Strongyloides stercoralis in a patient with HTLV-1 infection. 62
35833224 2022
31
Various types of electrochemical biosensors for leukemia detection and therapeutic approaches. 62
35588855 2022
32
The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development. 62
36358677 2022
33
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients. 62
36181532 2022
34
Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. 62
36261387 2022
35
HTLV infection in Brazil's second-largest indigenous reserve. 62
36202887 2022
36
Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. 62
36243685 2022
37
Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation. 62
36290777 2022
38
Particularities of Neurological Manifestations in Adult T-Cell Leukemia/Lymphoma: Need for a Multidisciplinary Approach-A Narrative Review. 62
36363509 2022
39
TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. 62
36164124 2022
40
Signaling factors potentially associated to the pathogenesis of Adult T-cell leukemia /lymphoma: A network-analysis and novel findings assessment. 62
35868352 2022
41
The importance of the clinical classification of adult T-cell leukemia/lymphoma (ATLL) in the prognosis. 62
36260617 2022
42
[Clinical Study of Chemotherapy Combined with Antivirals for Adult T-cell Leukemia/Lymphoma]. 62
36208242 2022
43
HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management. 62
35880453 2022
44
[Murine Models of Chronic Viral Infections and Associated Cancers]. 62
36165012 2022
45
Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses. 62
36146843 2022
46
Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy. 62
36298708 2022
47
Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines. 62
36298639 2022
48
In silico identification of epitope-based vaccine candidates against HTLV-1. 62
33648421 2022
49
Panuveitis induced by donor-derived CD8+ T cells after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia. 62
36034764 2022
50
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. 62
35687761 2022

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

GO Terms for Human T-Cell Leukemia Virus Type 1

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.93 BST2 APOBEC3B APOBEC3A
2 negative regulation of viral genome replication GO:0045071 9.8 BST2 APOBEC3A
3 energy homeostasis GO:0097009 9.78 CRTC3 CRTC1
4 negative regulation of transposition GO:0010529 9.73 APOBEC3B APOBEC3A
5 DNA demethylation GO:0080111 9.71 APOBEC3B APOBEC3A
6 negative regulation of single stranded viral RNA replication via double stranded DNA intermediate GO:0045869 9.67 APOBEC3B APOBEC3A
7 cytidine deamination GO:0009972 9.62 APOBEC3A APOBEC3B
8 cytidine to uridine editing GO:0016554 9.56 APOBEC3A APOBEC3B
9 DNA cytosine deamination GO:0070383 9.46 APOBEC3B APOBEC3A
10 protein homotetramerization GO:0051289 9.43 CRTC3 CRTC2 CRTC1
11 positive regulation of CREB transcription factor activity GO:0032793 9.1 CRTC3 CRTC2 CRTC1

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytidine deaminase activity GO:0004126 9.46 APOBEC3B APOBEC3A
2 deoxycytidine deaminase activity GO:0047844 9.26 APOBEC3A APOBEC3B
3 cAMP response element binding protein binding GO:0008140 9.1 CRTC3 CRTC2 CRTC1

Sources for Human T-Cell Leukemia Virus Type 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....